Broadly neutralizing human antibodies against dengue virus identified by single B cell transcriptomics

  1. Natasha D Durham
  2. Aditi Agrawal
  3. Eric Waltari
  4. Derek Croote
  5. Fabio Zanini
  6. Mallorie Fouch
  7. Edgar Davidson
  8. Olivia Smith
  9. Esteban Carabajal
  10. John E Pak
  11. Benjamin J Doranz
  12. Makeda Robinson
  13. Ana M Sanz
  14. Ludwig L Albornoz
  15. Fernando Rosso
  16. Shirit Einav
  17. Stephen R Quake
  18. Krista M McCutcheon
  19. Leslie Goo  Is a corresponding author
  1. Chan Zuckerberg Biohub, United States
  2. Stanford University, United States
  3. Integral Molecular, Inc, United States
  4. Fundación Valle del Lili, Colombia
  5. Fred Hutchinson Cancer Research Center, United States

Abstract

Eliciting broadly neutralizing antibodies (bNAbs) against the four dengue virus serotypes (DENV1-4) that are spreading into new territories is an important goal of vaccine design. To define bNAb targets, we characterized 28 antibodies belonging to expanded and hypermutated clonal families identified by transcriptomic analysis of single plasmablasts from DENV-infected individuals. Among these, we identified J9 and J8, two somatically related bNAbs that potently neutralized DENV1-4. Mutagenesis studies showed that the major recognition determinants of these bNAbs are in E protein domain I, distinct from the only known class of human bNAbs against DENV with a well-defined epitope. B cell repertoire analysis from acute-phase peripheral blood suggested that J9 and J8 followed divergent somatic hypermutation pathways, and that a limited number of mutations was sufficient for neutralizing activity. Our study suggests multiple B cell evolutionary pathways leading to DENV bNAbs targeting a new epitope that can be exploited for vaccine design.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided for Figures 2, 4, and 6.

The following previously published data sets were used

Article and author information

Author details

  1. Natasha D Durham

    Infectious Disease Initiative, Chan Zuckerberg Biohub, San Francisco, United States
    Competing interests
    No competing interests declared.
  2. Aditi Agrawal

    Infectious Disease Initiative, Chan Zuckerberg Biohub, San Francisco, United States
    Competing interests
    No competing interests declared.
  3. Eric Waltari

    Infectious Disease Initiative, Chan Zuckerberg Biohub, San Francisco, United States
    Competing interests
    Eric Waltari, Inventor of the following patent application, which is co-owned by the Chan Zuckerberg Biohub and Stanford University: PCT patent application entitled ANTIBODIES AGAINST DENGUE VIRUS AND RELATED METHODS, Serial no. PCT/US2019/045427, filed August 7, 2019.
  4. Derek Croote

    Department of Bioengineering, Stanford University, Stanford, United States
    Competing interests
    Derek Croote, Inventor of the following patent application, which is co-owned by the Chan Zuckerberg Biohub and Stanford University: PCT patent application entitled ANTIBODIES AGAINST DENGUE VIRUS AND RELATED METHODS, Serial no. PCT/US2019/045427, filed August 7, 2019.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4907-1865
  5. Fabio Zanini

    Department of Bioengineering, Stanford University, Stanford, United States
    Competing interests
    Fabio Zanini, Inventor of the following patent application, which is co-owned by the Chan Zuckerberg Biohub and Stanford University: PCT patent application entitled ANTIBODIES AGAINST DENGUE VIRUS AND RELATED METHODS, Serial no. PCT/US2019/045427, filed August 7, 2019.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7097-8539
  6. Mallorie Fouch

    Integral Molecular, Inc, Philadelphia, United States
    Competing interests
    No competing interests declared.
  7. Edgar Davidson

    Integral Molecular, Inc, Philadelphia, United States
    Competing interests
    No competing interests declared.
  8. Olivia Smith

    Infectious Disease Initiative, Chan Zuckerberg Biohub, San Francisco, United States
    Competing interests
    No competing interests declared.
  9. Esteban Carabajal

    Infectious Disease Initiative, Chan Zuckerberg Biohub, San Francisco, United States
    Competing interests
    No competing interests declared.
  10. John E Pak

    Infectious Disease Initiative, Chan Zuckerberg Biohub, San Francisco, United States
    Competing interests
    No competing interests declared.
  11. Benjamin J Doranz

    Integral Molecular, Inc, Philadelphia, United States
    Competing interests
    No competing interests declared.
  12. Makeda Robinson

    Department of Medicine, Stanford University, Stanford, United States
    Competing interests
    No competing interests declared.
  13. Ana M Sanz

    Clinical Research Center, Fundación Valle del Lili, Cali, Colombia
    Competing interests
    No competing interests declared.
  14. Ludwig L Albornoz

    Pathology and Laboratory Department, Fundación Valle del Lili, Cali, Colombia
    Competing interests
    No competing interests declared.
  15. Fernando Rosso

    Clinical Research Center, Fundación Valle del Lili, Cali, Colombia
    Competing interests
    No competing interests declared.
  16. Shirit Einav

    Department of Medicine, Stanford University, Stanford, United States
    Competing interests
    Shirit Einav, Inventor of the following patent application, which is co-owned by the Chan Zuckerberg Biohub and Stanford University: PCT patent application entitled ANTIBODIES AGAINST DENGUE VIRUS AND RELATED METHODS, Serial no. PCT/US2019/045427, filed August 7, 2019.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6441-4171
  17. Stephen R Quake

    Infectious Disease Initiative, Chan Zuckerberg Biohub, San Francisco, United States
    Competing interests
    Stephen R Quake, Inventor of the following patent application, which is co-owned by the Chan Zuckerberg Biohub and Stanford University: PCT patent application entitled ANTIBODIES AGAINST DENGUE VIRUS AND RELATED METHODS, Serial no. PCT/US2019/045427, filed August 7, 2019.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1613-0809
  18. Krista M McCutcheon

    Infectious Disease Initiative, Chan Zuckerberg Biohub, San Francisco, United States
    Competing interests
    Krista M McCutcheon, Inventor of the following patent application, which is co-owned by the Chan Zuckerberg Biohub and Stanford University: PCT patent application entitled ANTIBODIES AGAINST DENGUE VIRUS AND RELATED METHODS, Serial no. PCT/US2019/045427, filed August 7, 2019.
  19. Leslie Goo

    Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, United States
    For correspondence
    lgoo@fredhutch.org
    Competing interests
    Leslie Goo, Inventor of the following patent application, which is co-owned by the Chan Zuckerberg Biohub and Stanford University: PCT patent application entitled ANTIBODIES AGAINST DENGUE VIRUS AND RELATED METHODS, Serial no. PCT/US2019/045427, filed August 7, 2019.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3866-6735

Funding

Chan Zuckerberg Biohub

  • Natasha D Durham
  • Aditi Agrawal
  • Eric Waltari
  • Fabio Zanini
  • Olivia Smith
  • Esteban Carabajal
  • John E Pak
  • Stephen R Quake
  • Krista M McCutcheon
  • Leslie Goo

Fred Hutchinson Cancer Research Center

  • Leslie Goo

National Institutes of Health (HHSN272201400058C)

  • Benjamin J Doranz

NSF Graduate Research Fellowship

  • Derek Croote

Kou-I Yeh Stanford Graduate Fellowship

  • Derek Croote

Catalyst Award from Dr Ralph and Marian Falk Medical Research Trust

  • Shirit Einav

Stanford Bio-X Interdisciplinary Initiatives Seed Grants Program

  • Shirit Einav

Stanford Advanced Residency Training at Stanford Fellowship Program

  • Makeda Robinson

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: The study was approved by the Stanford University Administrative Panel on Human Subjects in Medical Research (Protocol #35460) and the Fundación Valle del Lili Ethics committee in biomedical research (Cali, Colombia). All subjects, their parents, or legal guardians provided written informed consent, and subjects between 6 to 17 years of age and older provided assent.

Copyright

© 2019, Durham et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 5,912
    views
  • 757
    downloads
  • 52
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Natasha D Durham
  2. Aditi Agrawal
  3. Eric Waltari
  4. Derek Croote
  5. Fabio Zanini
  6. Mallorie Fouch
  7. Edgar Davidson
  8. Olivia Smith
  9. Esteban Carabajal
  10. John E Pak
  11. Benjamin J Doranz
  12. Makeda Robinson
  13. Ana M Sanz
  14. Ludwig L Albornoz
  15. Fernando Rosso
  16. Shirit Einav
  17. Stephen R Quake
  18. Krista M McCutcheon
  19. Leslie Goo
(2019)
Broadly neutralizing human antibodies against dengue virus identified by single B cell transcriptomics
eLife 8:e52384.
https://doi.org/10.7554/eLife.52384

Share this article

https://doi.org/10.7554/eLife.52384

Further reading

    1. Cell Biology
    2. Immunology and Inflammation
    Mykhailo Vladymyrov, Luca Marchetti ... Britta Engelhardt
    Tools and Resources

    The endothelial blood-brain barrier (BBB) strictly controls immune cell trafficking into the central nervous system (CNS). In neuroinflammatory diseases such as multiple sclerosis, this tight control is, however, disturbed, leading to immune cell infiltration into the CNS. The development of in vitro models of the BBB combined with microfluidic devices has advanced our understanding of the cellular and molecular mechanisms mediating the multistep T-cell extravasation across the BBB. A major bottleneck of these in vitro studies is the absence of a robust and automated pipeline suitable for analyzing and quantifying the sequential interaction steps of different immune cell subsets with the BBB under physiological flow in vitro. Here, we present the under-flow migration tracker (UFMTrack) framework for studying immune cell interactions with endothelial monolayers under physiological flow. We then showcase a pipeline built based on it to study the entire multistep extravasation cascade of immune cells across brain microvascular endothelial cells under physiological flow in vitro. UFMTrack achieves 90% track reconstruction efficiency and allows for scaling due to the reduction of the analysis cost and by eliminating experimenter bias. This allowed for an in-depth analysis of all behavioral regimes involved in the multistep immune cell extravasation cascade. The study summarizes how UFMTrack can be employed to delineate the interactions of CD4+ and CD8+ T cells with the BBB under physiological flow. We also demonstrate its applicability to the other BBB models, showcasing broader applicability of the developed framework to a range of immune cell-endothelial monolayer interaction studies. The UFMTrack framework along with the generated datasets is publicly available in the corresponding repositories.

    1. Immunology and Inflammation
    Graham L Barlow, Christian M Schürch ... Paul L Bollyky
    Research Article

    In autoimmune type 1 diabetes (T1D), immune cells infiltrate and destroy the islets of Langerhans — islands of endocrine tissue dispersed throughout the pancreas. However, the contribution of cellular programs outside islets to insulitis is unclear. Here, using CO-Detection by indEXing (CODEX) tissue imaging and cadaveric pancreas samples, we simultaneously examine islet and extra-islet inflammation in human T1D. We identify four sub-states of inflamed islets characterized by the activation profiles of CD8+T cells enriched in islets relative to the surrounding tissue. We further find that the extra-islet space of lobules with extensive islet-infiltration differs from the extra-islet space of less infiltrated areas within the same tissue section. Finally, we identify lymphoid structures away from islets enriched in CD45RA+ T cells — a population also enriched in one of the inflamed islet sub-states. Together, these data help define the coordination between islets and the extra-islet pancreas in the pathogenesis of human T1D.